文献

J-GLOBAL ID：201702253122761953   整理番号：17A1628808

受容体チロシンキナーゼc-MET限界癌免疫療法に依存する反応性好中球応答【Powered by NICT】

Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy

著者 (48件)： Glodde Nicole (Laboratory of Experimental Dermatology, Department of Dermatology, University of Magdeburg, 39120 Magdeburg, Germany) ,  Glodde Nicole (Laboratory of Experimental Dermatology, Department of Dermatology and Allergy, University of Bonn, 53105 Bonn, Germany) ,  Glodde Nicole (Unit for RNA Biology, Department of Clinical Chemistry and Clinical Pharmacology, University of Bonn, 53105 Bonn, Germany) ,  Bald Tobias (Laboratory of Experimental Dermatology, Department of Dermatology, University of Magdeburg, 39120 Magdeburg, Germany) ,  Bald Tobias (Laboratory of Experimental Dermatology, Department of Dermatology and Allergy, University of Bonn, 53105 Bonn, Germany) ,  Bald Tobias (Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia) ,  van den Boorn-Konijnenberg Debby (Unit for RNA Biology, Department of Clinical Chemistry and Clinical Pharmacology, University of Bonn, 53105 Bonn, Germany) ,  Nakamura Kyohei (Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia) ,  O’Donnell Jake S. (Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia) ,  O’Donnell Jake S. (Cancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia) ,  O’Donnell Jake S. (School of Medicine, The University of Queensland, Herston, QLD 4006, Australia) ,  Szczepanski Sabrina (Department of Internal Medicine III, Hematology/Oncology/Rheumatology, University of Bonn, 53105 Bonn, Germany) ,  Brandes Maria (Department of Internal Medicine III, Hematology/Oncology/Rheumatology, University of Bonn, 53105 Bonn, Germany) ,  Eickhoff Sarah (Laboratory for Cellular Interactions and Immunimaging, Institute of Experimental Immunology, University of Bonn, 53105 Bonn, Germany) ,  Das Indrajit (Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia) ,  Shridhar Naveen (Laboratory of Experimental Dermatology, Department of Dermatology, University of Magdeburg, 39120 Magdeburg, Germany) ,  Shridhar Naveen (Laboratory of Experimental Dermatology, Department of Dermatology and Allergy, University of Bonn, 53105 Bonn, Germany) ,  Hinze Daniel (Unit for RNA Biology, Department of Clinical Chemistry and Clinical Pharmacology, University of Bonn, 53105 Bonn, Germany) ,  Rogava Meri (Laboratory of Experimental Dermatology, Department of Dermatology, University of Magdeburg, 39120 Magdeburg, Germany) ,  Rogava Meri (Laboratory of Experimental Dermatology, Department of Dermatology and Allergy, University of Bonn, 53105 Bonn, Germany) ,  van der Sluis Tetje C. (Laboratory of Experimental Dermatology, Department of Dermatology, University of Magdeburg, 39120 Magdeburg, Germany) ,  van der Sluis Tetje C. (Laboratory of Experimental Dermatology, Department of Dermatology and Allergy, University of Bonn, 53105 Bonn, Germany) ,  Ruotsalainen Janne J. (Laboratory of Experimental Dermatology, Department of Dermatology, University of Magdeburg, 39120 Magdeburg, Germany) ,  Ruotsalainen Janne J. (Laboratory of Experimental Dermatology, Department of Dermatology and Allergy, University of Bonn, 53105 Bonn, Germany) ,  Gaffal Evelyn (Laboratory of Experimental Dermatology, Department of Dermatology, University of Magdeburg, 39120 Magdeburg, Germany) ,  Gaffal Evelyn (Laboratory of Experimental Dermatology, Department of Dermatology and Allergy, University of Bonn, 53105 Bonn, Germany) ,  Landsberg Jennifer (Laboratory of Experimental Dermatology, Department of Dermatology and Allergy, University of Bonn, 53105 Bonn, Germany) ,  Ludwig Kerstin U. (Institute of Human Genetics, University of Bonn, 53127 Bonn, Germany) ,  Ludwig Kerstin U. (Department of Genomics, Life & Brain Center, University of Bonn, 53127 Bonn, Germany) ,  Wilhelm Christoph (Unit for Immunopathology, Department of Clinical Chemistry and Clinical Pharmacology, University of Bonn, 53105 Bonn, Germany) ,  Riek-Burchardt Monika (Institute of Molecular and Clinical Immunology, University of Magdeburg, 39120 Magdeburg, Germany) ,  Mueller Andreas J. (Institute of Molecular and Clinical Immunology, University of Magdeburg, 39120 Magdeburg, Germany) ,  Mueller Andreas J. (Helmholtz Centre for Infection Research (HZI), 38124 Braunschweig, Germany) ,  Gebhardt Christoffer (Skin Cancer Unit, German Cancer Research Center, Heidelberg and Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht Karl University of Heidelberg, 69121 Heidelberg, Germany) ,  Scolyer Richard A. (Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia) ,  Scolyer Richard A. (Melanoma Institute Australia and Sydney Medical School, The University of Sydney, Sydney, NSW 2065, Australia) ,  Long Georgina V. (Melanoma Institute Australia and Sydney Medical School, The University of Sydney, Sydney, NSW 2065, Australia) ,  Janzen Viktor (Department of Internal Medicine III, Hematology/Oncology/Rheumatology, University of Bonn, 53105 Bonn, Germany) ,  Teng Michele W.L. (Cancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia) ,  Teng Michele W.L. (School of Medicine, The University of Queensland, Herston, QLD 4006, Australia) ,  Kastenmueller Wolfgang (Laboratory for Cellular Interactions and Immunimaging, Institute of Experimental Immunology, University of Bonn, 53105 Bonn, Germany) ,  Mazzone Massimiliano (Laboratory of Molecular Oncology and Angiogenesis, Vesalius Research Center, VIB, Leuven B3000, Belgium) ,  Mazzone Massimiliano (Laboratory of Molecular Oncology and Angiogenesis, Vesalius Research Center, Department of Oncology, KU Leuven, Leuven B3000, Belgium) ,  Smyth Mark J. (Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia) ,  Smyth Mark J. (School of Medicine, The University of Queensland, Herston, QLD 4006, Australia) ,  Tueting Thomas (Laboratory of Experimental Dermatology, Department of Dermatology, University of Magdeburg, 39120 Magdeburg, Germany) ,  Tueting Thomas (Laboratory of Experimental Dermatology, Department of Dermatology and Allergy, University of Bonn, 53105 Bonn, Germany) ,  Holzel Michael (Unit for RNA Biology, Department of Clinical Chemistry and Clinical Pharmacology, University of Bonn, 53105 Bonn, Germany)
資料名： Immunity  (Immunity)
巻： 47  号： 4  ページ： 789-802.e9  発行年： 2017年 
JST資料番号： W1727A  ISSN： 1074-7613  資料種別： 逐次刊行物 (A)
記事区分： 原著論文  発行国： オランダ (NLD)  言語： 英語 (EN)

抄録/ポイント： 受容体チロシンキナーゼc-METの阻害剤は現在,腫瘍細胞における発癌性シグナル伝達を標的とする臨床で用いられている。はc-MET阻害は,腫瘍におけるエフェクターT細胞浸潤を増加させることによりマウス癌モデルにおける養子T細胞移入とチェックポイント免疫療法を促進することを見出した。治療効果は腫瘍細胞固有のc-MET依存性とは無関係であった。機構的に,c-MET阻害は細胞毒性免疫療法に応答した腫瘍および流入領域リンパ節への好中球の反応性動員と動員を阻害した。c-MET阻害の非存在下では,T細胞炎症微小環境へ動員された好中球は免疫抑制特性,拘束T細胞増殖とエフェクター機能を獲得した。癌患者では,c-MET配位子HGFの高血清レベルはチェックポイント遮断療法への好中球数および悪い反応の増加と相関していた。著者らの知見は,好中球動員と機能におけるHGF/c MET経路の役割を明らかにし,c-MET阻害剤共処理は,C MET依存性腫瘍を越えた環境における癌免疫療法への応答を改善する可能性があることを示唆した。Copyright 2017 Elsevier B.V., Amsterdam. All rights reserved. Translated from English into Japanese by JST.【Powered by NICT】

シソーラス用語： *好中球 ,  腫瘍細胞 ,  炎症 ,  血清中濃度 ,  免疫抑制 ,  *反応性 ,  *治療法 ,  リンパ節 ,  *受容体型チロシンキナーゼ ,  発癌性 ,  細胞毒性 ,  腫瘍 ,  *免疫療法 ,  T細胞
準シソーラス用語： *癌免疫療法 , 【Automatic Indexing@JST】

著者キーワード (10件)： c-MET ,  HGF ,  好中球 ,  plasticity ,  癌免疫療法 ,  melanoma ,  リンパ節 ,  骨髄 ,  治療抵抗性 ,  T細胞

分類 (2件)： 分子構造  (EB03020Y) ,  腫ようの免疫療法  (GE03035B)

タイトルに関連する用語 (7件)： 受容体チロシンキナーゼ ,  c-met ,  限界 ,  癌免疫療法 ,  反応性 ,  好中球 ,  応答